AEMDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends March 31
AETHLON MEDICAL INC
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.16+0.01 (+0.19%)
Close on Oct 19, 2026
- Market cap
- $1.99M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | -652.8% | -83.7% | -142.9% | |
| Return on assets | -342.0% | -74.9% | -104.5% | |
| Current ratio | 2.61 | 7.53 | 3.85 | |
| Interest coverage | – | – | -507.5× | |
| Capex to revenue | 4.2% | 9.1% | – | |
| Diluted shares | 0M | 0M | 1M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Aethlon Medical generated $45.05M from operations and spent $1.55M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$45.05M
Used
$1.55M
Capital expenditure$1.55M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-2094.9%
×Asset turnover0.03×
×Equity multiplier1.15×
=Return on equity, FY2023-75.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2023 | -2094.9% | 0.03× | 1.15× | -75.1% |
| FY2022 | -3540.9% | 0.02× | 1.14× | -78.8% |
| FY2021 | -1196.6% | 0.06× | 1.12× | -83.7% |
| FY2020 | -980.3% | 0.09× | 1.23× | -107.7% |
| FY2019 | -2697.8% | 0.04× | 1.34× | -144.8% |
| FY2018 | -3795.9% | 0.03× | 1.33× | -166.8% |
| FY2017 | -1855.8% | 0.18× | 1.91× | -652.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
3of 6 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$7.15M
- Cash generatingOperating cash flow above zero-$7.00M
- Return on assets improvedROA up on the prior year-162.4% → -97.2%
- Earnings backed by cashOperating cash flow above net income-$7.00M vs -$7.15M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.13 → 3.85
- No dilutionShare count did not rise0M → 1M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –